iBio (IBIO) risk factors

70 risks, 18 new, 11 dropped, 14 reworded since the prior year. IBIO-600 is now in a Phase 1 Australian trial, adding country-specific regulatory, enrollment, CRO and FDA-data-acceptance exposure.

63 risks, 18 new, 10 dropped, 10 reworded since the prior year. iBio faces severe going concern risks with an accumulated deficit of $332.2 million as of June 30, 2025. Raising capital is constrained because its public float dropped to approximately $20.0 million, well below the $75.0 million threshold. All product candidates remain in preclinical development, focusing primarily on cardiometabolic and obesity fields.

55 risks. The risk profile is dominated by severe liquidity concerns, ongoing operating losses, and a looming going concern doubt. The company faces high dependence on third-party manufacturers, unproven artificial intelligence drug discovery technologies, and early-stage preclinical assets. Operations are threatened by the need for additional capital raising, which risks significant dilution for existing stockholders.